Exact Mass: 487.35088440000004
Exact Mass Matches: 487.35088440000004
Found 262 metabolites which its exact mass value is equals to given mass value 487.35088440000004
,
within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error
0.01 dalton.
(4Z,7Z,10Z,13Z,15E,19Z)-17-Hydroxydocosa-4,7,10,13,15,19-hexaenoylcarnitine
C29H45NO5 (487.32975600000003)
(4Z,7Z,10Z,13Z,15E,19Z)-17-hydroxydocosa-4,7,10,13,15,19-hexaenoylcarnitine is an acylcarnitine. More specifically, it is an (4Z,7Z,10Z,13Z,15E,19Z)-17-hydroxydocosa-4,7,10,13,15,19-hexaenoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. (4Z,7Z,10Z,13Z,15E,19Z)-17-hydroxydocosa-4,7,10,13,15,19-hexaenoylcarnitine is therefore classified as a very-long chain AC. As a very long-chain acylcarnitine (4Z,7Z,10Z,13Z,15E,19Z)-17-hydroxydocosa-4,7,10,13,15,19-hexaenoylcarnitine is generally formed in the cytoplasm from very long acyl groups synthesized by fatty acid synthases or obtained from the diet. Very-long-chain fatty acids are generally too long to be involved in mitochondrial beta-oxidation. As a result peroxisomes are the main organelle where very-long-chain fatty acids are metabolized and their acylcarnitines synthesized (PMID: 18793625). Altered levels of very long-chain acylcarnitines can serve as useful markers for inherited disorders of peroxisomal metabolism. The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].
(4Z,7Z,11Z,13Z,16Z,19Z)-10-Hydroxydocosa-4,7,11,13,16,19-hexaenoylcarnitine
C29H45NO5 (487.32975600000003)
(4Z,7Z,11Z,13Z,16Z,19Z)-10-hydroxydocosa-4,7,11,13,16,19-hexaenoylcarnitine is an acylcarnitine. More specifically, it is an (4Z,7Z,11Z,13Z,16Z,19Z)-10-hydroxydocosa-4,7,11,13,16,19-hexaenoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. (4Z,7Z,11Z,13Z,16Z,19Z)-10-hydroxydocosa-4,7,11,13,16,19-hexaenoylcarnitine is therefore classified as a very-long chain AC. As a very long-chain acylcarnitine (4Z,7Z,11Z,13Z,16Z,19Z)-10-hydroxydocosa-4,7,11,13,16,19-hexaenoylcarnitine is generally formed in the cytoplasm from very long acyl groups synthesized by fatty acid synthases or obtained from the diet. Very-long-chain fatty acids are generally too long to be involved in mitochondrial beta-oxidation. As a result peroxisomes are the main organelle where very-long-chain fatty acids are metabolized and their acylcarnitines synthesized (PMID: 18793625). Altered levels of very long-chain acylcarnitines can serve as useful markers for inherited disorders of peroxisomal metabolism. The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].
(4Z,7E,9E,13Z,16Z,19Z)-11-Hydroxydocosa-4,7,9,13,16,19-hexaenoylcarnitine
C29H45NO5 (487.32975600000003)
(4Z,7E,9E,13Z,16Z,19Z)-11-hydroxydocosa-4,7,9,13,16,19-hexaenoylcarnitine is an acylcarnitine. More specifically, it is an (4Z,7E,9E,13Z,16Z,19Z)-11-hydroxydocosa-4,7,9,13,16,19-hexaenoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. (4Z,7E,9E,13Z,16Z,19Z)-11-hydroxydocosa-4,7,9,13,16,19-hexaenoylcarnitine is therefore classified as a very-long chain AC. As a very long-chain acylcarnitine (4Z,7E,9E,13Z,16Z,19Z)-11-hydroxydocosa-4,7,9,13,16,19-hexaenoylcarnitine is generally formed in the cytoplasm from very long acyl groups synthesized by fatty acid synthases or obtained from the diet. Very-long-chain fatty acids are generally too long to be involved in mitochondrial beta-oxidation. As a result peroxisomes are the main organelle where very-long-chain fatty acids are metabolized and their acylcarnitines synthesized (PMID: 18793625). Altered levels of very long-chain acylcarnitines can serve as useful markers for inherited disorders of peroxisomal metabolism. The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].
(4Z,7Z,10Z,14E,16Z,19Z)-13-Hydroxydocosa-4,7,10,14,16,19-hexaenoylcarnitine
C29H45NO5 (487.32975600000003)
(4Z,7Z,10Z,14E,16Z,19Z)-13-hydroxydocosa-4,7,10,14,16,19-hexaenoylcarnitine is an acylcarnitine. More specifically, it is an (4Z,7Z,10Z,14E,16Z,19Z)-13-hydroxydocosa-4,7,10,14,16,19-hexaenoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. (4Z,7Z,10Z,14E,16Z,19Z)-13-hydroxydocosa-4,7,10,14,16,19-hexaenoylcarnitine is therefore classified as a very-long chain AC. As a very long-chain acylcarnitine (4Z,7Z,10Z,14E,16Z,19Z)-13-hydroxydocosa-4,7,10,14,16,19-hexaenoylcarnitine is generally formed in the cytoplasm from very long acyl groups synthesized by fatty acid synthases or obtained from the diet. Very-long-chain fatty acids are generally too long to be involved in mitochondrial beta-oxidation. As a result peroxisomes are the main organelle where very-long-chain fatty acids are metabolized and their acylcarnitines synthesized (PMID: 18793625). Altered levels of very long-chain acylcarnitines can serve as useful markers for inherited disorders of peroxisomal metabolism. The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].
(4Z,7Z,10Z,13Z,17Z,19Z)-16-Hydroxydocosa-4,7,10,13,17,19-hexaenoylcarnitine
C29H45NO5 (487.32975600000003)
(4Z,7Z,10Z,13Z,17Z,19Z)-16-hydroxydocosa-4,7,10,13,17,19-hexaenoylcarnitine is an acylcarnitine. More specifically, it is an (4Z,7Z,10Z,13Z,17Z,19Z)-16-hydroxydocosa-4,7,10,13,17,19-hexaenoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. (4Z,7Z,10Z,13Z,17Z,19Z)-16-hydroxydocosa-4,7,10,13,17,19-hexaenoylcarnitine is therefore classified as a very-long chain AC. As a very long-chain acylcarnitine (4Z,7Z,10Z,13Z,17Z,19Z)-16-hydroxydocosa-4,7,10,13,17,19-hexaenoylcarnitine is generally formed in the cytoplasm from very long acyl groups synthesized by fatty acid synthases or obtained from the diet. Very-long-chain fatty acids are generally too long to be involved in mitochondrial beta-oxidation. As a result peroxisomes are the main organelle where very-long-chain fatty acids are metabolized and their acylcarnitines synthesized (PMID: 18793625). Altered levels of very long-chain acylcarnitines can serve as useful markers for inherited disorders of peroxisomal metabolism. The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].
(4Z,7Z,10Z,13Z,16E,18E)-20-Hydroxydocosa-4,7,10,13,16,18-hexaenoylcarnitine
C29H45NO5 (487.32975600000003)
(4Z,7Z,10Z,13Z,16E,18E)-20-hydroxydocosa-4,7,10,13,16,18-hexaenoylcarnitine is an acylcarnitine. More specifically, it is an (4Z,7Z,10Z,13Z,16E,18E)-20-hydroxydocosa-4,7,10,13,16,18-hexaenoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. (4Z,7Z,10Z,13Z,16E,18E)-20-hydroxydocosa-4,7,10,13,16,18-hexaenoylcarnitine is therefore classified as a very-long chain AC. As a very long-chain acylcarnitine (4Z,7Z,10Z,13Z,16E,18E)-20-hydroxydocosa-4,7,10,13,16,18-hexaenoylcarnitine is generally formed in the cytoplasm from very long acyl groups synthesized by fatty acid synthases or obtained from the diet. Very-long-chain fatty acids are generally too long to be involved in mitochondrial beta-oxidation. As a result peroxisomes are the main organelle where very-long-chain fatty acids are metabolized and their acylcarnitines synthesized (PMID: 18793625). Altered levels of very long-chain acylcarnitines can serve as useful markers for inherited disorders of peroxisomal metabolism. The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].
(5Z,7Z,10Z,13Z,16Z,19Z)-4-Hydroxydocosa-5,7,10,13,16,19-hexaenoylcarnitine
C29H45NO5 (487.32975600000003)
(5Z,7Z,10Z,13Z,16Z,19Z)-4-hydroxydocosa-5,7,10,13,16,19-hexaenoylcarnitine is an acylcarnitine. More specifically, it is an (5Z,7Z,10Z,13Z,16Z,19Z)-4-hydroxydocosa-5,7,10,13,16,19-hexaenoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. (5Z,7Z,10Z,13Z,16Z,19Z)-4-hydroxydocosa-5,7,10,13,16,19-hexaenoylcarnitine is therefore classified as a very-long chain AC. As a very long-chain acylcarnitine (5Z,7Z,10Z,13Z,16Z,19Z)-4-hydroxydocosa-5,7,10,13,16,19-hexaenoylcarnitine is generally formed in the cytoplasm from very long acyl groups synthesized by fatty acid synthases or obtained from the diet. Very-long-chain fatty acids are generally too long to be involved in mitochondrial beta-oxidation. As a result peroxisomes are the main organelle where very-long-chain fatty acids are metabolized and their acylcarnitines synthesized (PMID: 18793625). Altered levels of very long-chain acylcarnitines can serve as useful markers for inherited disorders of peroxisomal metabolism. The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].
(4Z,8Z,10Z,13Z,16Z,19Z)-7-Hydroxydocosa-4,8,10,13,16,19-hexaenoylcarnitine
C29H45NO5 (487.32975600000003)
(4Z,8Z,10Z,13Z,16Z,19Z)-7-hydroxydocosa-4,8,10,13,16,19-hexaenoylcarnitine is an acylcarnitine. More specifically, it is an (4Z,8Z,10Z,13Z,16Z,19Z)-7-hydroxydocosa-4,8,10,13,16,19-hexaenoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. (4Z,8Z,10Z,13Z,16Z,19Z)-7-hydroxydocosa-4,8,10,13,16,19-hexaenoylcarnitine is therefore classified as a very-long chain AC. As a very long-chain acylcarnitine (4Z,8Z,10Z,13Z,16Z,19Z)-7-hydroxydocosa-4,8,10,13,16,19-hexaenoylcarnitine is generally formed in the cytoplasm from very long acyl groups synthesized by fatty acid synthases or obtained from the diet. Very-long-chain fatty acids are generally too long to be involved in mitochondrial beta-oxidation. As a result peroxisomes are the main organelle where very-long-chain fatty acids are metabolized and their acylcarnitines synthesized (PMID: 18793625). Altered levels of very long-chain acylcarnitines can serve as useful markers for inherited disorders of peroxisomal metabolism. The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].
(4E,6E,10Z,13Z,16Z,19Z)-8-Hydroxydocosa-4,6,10,13,16,19-hexaenoylcarnitine
C29H45NO5 (487.32975600000003)
(4E,6E,10Z,13Z,16Z,19Z)-8-hydroxydocosa-4,6,10,13,16,19-hexaenoylcarnitine is an acylcarnitine. More specifically, it is an (4E,6E,10Z,13Z,16Z,19Z)-8-hydroxydocosa-4,6,10,13,16,19-hexaenoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. (4E,6E,10Z,13Z,16Z,19Z)-8-hydroxydocosa-4,6,10,13,16,19-hexaenoylcarnitine is therefore classified as a very-long chain AC. As a very long-chain acylcarnitine (4E,6E,10Z,13Z,16Z,19Z)-8-hydroxydocosa-4,6,10,13,16,19-hexaenoylcarnitine is generally formed in the cytoplasm from very long acyl groups synthesized by fatty acid synthases or obtained from the diet. Very-long-chain fatty acids are generally too long to be involved in mitochondrial beta-oxidation. As a result peroxisomes are the main organelle where very-long-chain fatty acids are metabolized and their acylcarnitines synthesized (PMID: 18793625). Altered levels of very long-chain acylcarnitines can serve as useful markers for inherited disorders of peroxisomal metabolism. The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].
(4Z,7Z,10Z,13Z,16Z)-18-(3-Ethyloxiran-2-yl)octadeca-4,7,10,13,16-pentaenoylcarnitine
C29H45NO5 (487.32975600000003)
(4Z,7Z,10Z,13Z,16Z)-18-(3-ethyloxiran-2-yl)octadeca-4,7,10,13,16-pentaenoylcarnitine is an acylcarnitine. More specifically, it is an (4Z,7Z,10Z,13Z,16Z)-18-(3-ethyloxiran-2-yl)octadeca-4,7,10,13,16-pentaenoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. (4Z,7Z,10Z,13Z,16Z)-18-(3-ethyloxiran-2-yl)octadeca-4,7,10,13,16-pentaenoylcarnitine is therefore classified as a very-long chain AC. As a very long-chain acylcarnitine (4Z,7Z,10Z,13Z,16Z)-18-(3-ethyloxiran-2-yl)octadeca-4,7,10,13,16-pentaenoylcarnitine is generally formed in the cytoplasm from very long acyl groups synthesized by fatty acid synthases or obtained from the diet. Very-long-chain fatty acids are generally too long to be involved in mitochondrial beta-oxidation. As a result peroxisomes are the main organelle where very-long-chain fatty acids are metabolized and their acylcarnitines synthesized (PMID: 18793625). Altered levels of very long-chain acylcarnitines can serve as useful markers for inherited disorders of peroxisomal metabolism. The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].
(4Z,7Z,10Z,13Z)-15-{3-[(2Z)-Pent-2-en-1-yl]oxiran-2-yl}pentadeca-4,7,10,13-tetraenoylcarnitine
C29H45NO5 (487.32975600000003)
(4Z,7Z,10Z,13Z)-15-{3-[(2Z)-pent-2-en-1-yl]oxiran-2-yl}pentadeca-4,7,10,13-tetraenoylcarnitine is an acylcarnitine. More specifically, it is an (4Z,7Z,10Z,13Z)-15-{3-[(2Z)-pent-2-en-1-yl]oxiran-2-yl}pentadeca-4,7,10,13-tetraenoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. (4Z,7Z,10Z,13Z)-15-{3-[(2Z)-pent-2-en-1-yl]oxiran-2-yl}pentadeca-4,7,10,13-tetraenoylcarnitine is therefore classified as a very-long chain AC. As a very long-chain acylcarnitine (4Z,7Z,10Z,13Z)-15-{3-[(2Z)-pent-2-en-1-yl]oxiran-2-yl}pentadeca-4,7,10,13-tetraenoylcarnitine is generally formed in the cytoplasm from very long acyl groups synthesized by fatty acid synthases or obtained from the diet. Very-long-chain fatty acids are generally too long to be involved in mitochondrial beta-oxidation. As a result peroxisomes are the main organelle where very-long-chain fatty acids are metabolized and their acylcarnitines synthesized (PMID: 18793625). Altered levels of very long-chain acylcarnitines can serve as useful markers for inherited disorders of peroxisomal metabolism. The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].
Talaroconvolutin A
An octahydronaphthalene with formula C32H41NO3. It is a fungal metabolite isolated from Talaromyces convolutus and is an inducer of ferroptosis in colorectal cancer cells.
Batzelladine L|beauveriolide I|beauverolide I
C27H41N3O5 (487.30460560000006)
23-O-Acetyl-12beta-hydroxy-solasodin
C29H45NO5 (487.32975600000003)
Asn Val Lys Lys
C21H41N7O6 (487.31181660000004)
Asn Lys Val Lys
C21H41N7O6 (487.31181660000004)
Thr Ile Val Arg
C21H41N7O6 (487.31181660000004)
Gly Lys Lys Arg
C20H41N9O5 (487.32304960000005)
Gly Lys Arg Lys
C20H41N9O5 (487.32304960000005)
Gly Arg Lys Lys
C20H41N9O5 (487.32304960000005)
Ile Ile Arg Ser
C21H41N7O6 (487.31181660000004)
Ile Ile Ser Arg
C21H41N7O6 (487.31181660000004)
Ile Leu Arg Ser
C21H41N7O6 (487.31181660000004)
Ile Leu Ser Arg
C21H41N7O6 (487.31181660000004)
Ile Arg Ile Ser
C21H41N7O6 (487.31181660000004)
Ile Arg Leu Ser
C21H41N7O6 (487.31181660000004)
Ile Arg Ser Ile
C21H41N7O6 (487.31181660000004)
Ile Arg Ser Leu
C21H41N7O6 (487.31181660000004)
Ile Arg Thr Val
C21H41N7O6 (487.31181660000004)
Ile Arg Val Thr
C21H41N7O6 (487.31181660000004)
Ile Ser Ile Arg
C21H41N7O6 (487.31181660000004)
Ile Ser Leu Arg
C21H41N7O6 (487.31181660000004)
Ile Ser Arg Ile
C21H41N7O6 (487.31181660000004)
Ile Ser Arg Leu
C21H41N7O6 (487.31181660000004)
Ile Thr Arg Val
C21H41N7O6 (487.31181660000004)
Ile Thr Val Arg
C21H41N7O6 (487.31181660000004)
Ile Val Arg Thr
C21H41N7O6 (487.31181660000004)
Ile Val Thr Arg
C21H41N7O6 (487.31181660000004)
Lys Gly Lys Arg
C20H41N9O5 (487.32304960000005)
Lys Gly Arg Lys
C20H41N9O5 (487.32304960000005)
Lys Lys Gly Arg
C20H41N9O5 (487.32304960000005)
Lys Lys Asn Val
C21H41N7O6 (487.31181660000004)
Lys Lys Arg Gly
C20H41N9O5 (487.32304960000005)
Lys Lys Val Asn
C21H41N7O6 (487.31181660000004)
Lys Asn Lys Val
C21H41N7O6 (487.31181660000004)
Lys Asn Val Lys
C21H41N7O6 (487.31181660000004)
Lys Arg Gly Lys
C20H41N9O5 (487.32304960000005)
Lys Arg Lys Gly
C20H41N9O5 (487.32304960000005)
Lys Val Lys Asn
C21H41N7O6 (487.31181660000004)
Lys Val Asn Lys
C21H41N7O6 (487.31181660000004)
Leu Ile Arg Ser
C21H41N7O6 (487.31181660000004)
Leu Ile Ser Arg
C21H41N7O6 (487.31181660000004)
Leu Leu Arg Ser
C21H41N7O6 (487.31181660000004)
Leu Leu Ser Arg
C21H41N7O6 (487.31181660000004)
Leu Arg Ile Ser
C21H41N7O6 (487.31181660000004)
Leu Arg Leu Ser
C21H41N7O6 (487.31181660000004)
Leu Arg Ser Ile
C21H41N7O6 (487.31181660000004)
Leu Arg Ser Leu
C21H41N7O6 (487.31181660000004)
Leu Arg Thr Val
C21H41N7O6 (487.31181660000004)
Leu Arg Val Thr
C21H41N7O6 (487.31181660000004)
Leu Ser Ile Arg
C21H41N7O6 (487.31181660000004)
Leu Ser Leu Arg
C21H41N7O6 (487.31181660000004)
Leu Ser Arg Ile
C21H41N7O6 (487.31181660000004)
Leu Ser Arg Leu
C21H41N7O6 (487.31181660000004)
Leu Thr Arg Val
C21H41N7O6 (487.31181660000004)
Leu Thr Val Arg
C21H41N7O6 (487.31181660000004)
Leu Val Arg Thr
C21H41N7O6 (487.31181660000004)
Leu Val Thr Arg
C21H41N7O6 (487.31181660000004)
Asn Lys Lys Val
C21H41N7O6 (487.31181660000004)
Arg Gly Lys Lys
C20H41N9O5 (487.32304960000005)
Arg Ile Ile Ser
C21H41N7O6 (487.31181660000004)
Arg Ile Leu Ser
C21H41N7O6 (487.31181660000004)
Arg Ile Ser Ile
C21H41N7O6 (487.31181660000004)
Arg Ile Ser Leu
C21H41N7O6 (487.31181660000004)
Arg Ile Thr Val
C21H41N7O6 (487.31181660000004)
Arg Ile Val Thr
C21H41N7O6 (487.31181660000004)
Arg Lys Gly Lys
C20H41N9O5 (487.32304960000005)
Arg Lys Lys Gly
C20H41N9O5 (487.32304960000005)
Arg Leu Ile Ser
C21H41N7O6 (487.31181660000004)
Arg Leu Leu Ser
C21H41N7O6 (487.31181660000004)
Arg Leu Ser Ile
C21H41N7O6 (487.31181660000004)
Arg Leu Ser Leu
C21H41N7O6 (487.31181660000004)
Arg Leu Thr Val
C21H41N7O6 (487.31181660000004)
Arg Leu Val Thr
C21H41N7O6 (487.31181660000004)
Arg Ser Ile Ile
C21H41N7O6 (487.31181660000004)
Arg Ser Ile Leu
C21H41N7O6 (487.31181660000004)
Arg Ser Leu Ile
C21H41N7O6 (487.31181660000004)
Arg Ser Leu Leu
C21H41N7O6 (487.31181660000004)
Arg Thr Ile Val
C21H41N7O6 (487.31181660000004)
Arg Thr Leu Val
C21H41N7O6 (487.31181660000004)
Arg Thr Val Ile
C21H41N7O6 (487.31181660000004)
Arg Thr Val Leu
C21H41N7O6 (487.31181660000004)
Arg Val Ile Thr
C21H41N7O6 (487.31181660000004)
Arg Val Leu Thr
C21H41N7O6 (487.31181660000004)
Arg Val Thr Ile
C21H41N7O6 (487.31181660000004)
Arg Val Thr Leu
C21H41N7O6 (487.31181660000004)
Ser Ile Ile Arg
C21H41N7O6 (487.31181660000004)
Ser Ile Leu Arg
C21H41N7O6 (487.31181660000004)
Ser Ile Arg Ile
C21H41N7O6 (487.31181660000004)
Ser Ile Arg Leu
C21H41N7O6 (487.31181660000004)
Ser Leu Ile Arg
C21H41N7O6 (487.31181660000004)
Ser Leu Leu Arg
C21H41N7O6 (487.31181660000004)
Ser Leu Arg Ile
C21H41N7O6 (487.31181660000004)
Ser Leu Arg Leu
C21H41N7O6 (487.31181660000004)
Ser Arg Ile Ile
C21H41N7O6 (487.31181660000004)
Ser Arg Ile Leu
C21H41N7O6 (487.31181660000004)
Ser Arg Leu Ile
C21H41N7O6 (487.31181660000004)
Ser Arg Leu Leu
C21H41N7O6 (487.31181660000004)
Thr Ile Arg Val
C21H41N7O6 (487.31181660000004)
Thr Leu Arg Val
C21H41N7O6 (487.31181660000004)
Thr Leu Val Arg
C21H41N7O6 (487.31181660000004)
Thr Arg Ile Val
C21H41N7O6 (487.31181660000004)
Thr Arg Leu Val
C21H41N7O6 (487.31181660000004)
Thr Arg Val Ile
C21H41N7O6 (487.31181660000004)
Thr Arg Val Leu
C21H41N7O6 (487.31181660000004)
Thr Val Ile Arg
C21H41N7O6 (487.31181660000004)
Thr Val Leu Arg
C21H41N7O6 (487.31181660000004)
Thr Val Arg Ile
C21H41N7O6 (487.31181660000004)
Thr Val Arg Leu
C21H41N7O6 (487.31181660000004)
Val Ile Arg Thr
C21H41N7O6 (487.31181660000004)
Val Ile Thr Arg
C21H41N7O6 (487.31181660000004)
Val Lys Lys Asn
C21H41N7O6 (487.31181660000004)
Val Lys Asn Lys
C21H41N7O6 (487.31181660000004)
Val Leu Arg Thr
C21H41N7O6 (487.31181660000004)
Val Leu Thr Arg
C21H41N7O6 (487.31181660000004)
Val Asn Lys Lys
C21H41N7O6 (487.31181660000004)
Val Arg Ile Thr
C21H41N7O6 (487.31181660000004)
Val Arg Leu Thr
C21H41N7O6 (487.31181660000004)
Val Arg Thr Ile
C21H41N7O6 (487.31181660000004)
Val Arg Thr Leu
C21H41N7O6 (487.31181660000004)
Val Thr Ile Arg
C21H41N7O6 (487.31181660000004)
Val Thr Leu Arg
C21H41N7O6 (487.31181660000004)
Val Thr Arg Ile
C21H41N7O6 (487.31181660000004)
Val Thr Arg Leu
C21H41N7O6 (487.31181660000004)
(Z)-2-pentacos-16-enamidoethanesulfonic acid
C27H53NO4S (487.36950980000006)
2-(8-[3]-ladderane-octanyl)-sn-glycero-3-phosphoethanolamine
C25H46NO6P (487.30625860000004)
LPE O-20:4
C25H46NO6P (487.30625860000004)
Poly(oxy-1,2-ethanediyl), .alpha.-sulfo- .omega.-(dinonylphenoxy)-, ammonium salt
C26H49NO5S (487.3331264000001)
1-Octanaminium,N-[2-[(2,2-dicyclopentylacetyl)oxy]ethyl]-N,N-diethyl-, bromide (1:1)
Beauveriolide I
C27H41N3O5 (487.30460560000006)
A cyclodepsipeptide with formula C27H41N3O5. It was originally isolated from the fungus Beauveria sp. FO-6979 during a screening program for inhibitors of lipid droplet accumulation in murine macrophages. It is an inhibitor of acyl-CoA: cholesterol acyltransferase (ACAT) and effective at reducing atherogenic lesions of the artery and heart in mouse models.
(4Z,7Z,10Z,13Z,15E,19Z)-17-Hydroxydocosa-4,7,10,13,15,19-hexaenoylcarnitine
C29H45NO5 (487.32975600000003)
(4Z,7Z,11Z,13Z,16Z,19Z)-10-Hydroxydocosa-4,7,11,13,16,19-hexaenoylcarnitine
C29H45NO5 (487.32975600000003)
(4Z,7E,9E,13Z,16Z,19Z)-11-Hydroxydocosa-4,7,9,13,16,19-hexaenoylcarnitine
C29H45NO5 (487.32975600000003)
(4Z,7Z,10Z,14E,16Z,19Z)-13-Hydroxydocosa-4,7,10,14,16,19-hexaenoylcarnitine
C29H45NO5 (487.32975600000003)
(4Z,7Z,10Z,13Z,17Z,19Z)-16-Hydroxydocosa-4,7,10,13,17,19-hexaenoylcarnitine
C29H45NO5 (487.32975600000003)
(4Z,7Z,10Z,13Z,16E,18E)-20-Hydroxydocosa-4,7,10,13,16,18-hexaenoylcarnitine
C29H45NO5 (487.32975600000003)
(5Z,7Z,10Z,13Z,16Z,19Z)-4-Hydroxydocosa-5,7,10,13,16,19-hexaenoylcarnitine
C29H45NO5 (487.32975600000003)
(4Z,8Z,10Z,13Z,16Z,19Z)-7-Hydroxydocosa-4,8,10,13,16,19-hexaenoylcarnitine
C29H45NO5 (487.32975600000003)
(4E,6E,10Z,13Z,16Z,19Z)-8-Hydroxydocosa-4,6,10,13,16,19-hexaenoylcarnitine
C29H45NO5 (487.32975600000003)
(4Z,7Z,10Z,13Z,16Z)-18-(3-Ethyloxiran-2-yl)octadeca-4,7,10,13,16-pentaenoylcarnitine
C29H45NO5 (487.32975600000003)
(4Z,7Z,10Z,13Z)-15-{3-[(2Z)-Pent-2-en-1-yl]oxiran-2-yl}pentadeca-4,7,10,13-tetraenoylcarnitine
C29H45NO5 (487.32975600000003)
[3-methyl-4-(3-methylphenyl)-1-piperazinyl]-[1-(7,8,9,10-tetrahydro-6H-purino[9,8-a]azepin-4-yl)-4-piperidinyl]methanone
(1S)-4-[4-[hydroxy(diphenyl)methyl]piperidin-1-yl]-1-[4-(1-hydroxy-2-methylpropan-2-yl)phenyl]butan-1-ol
N-[(4R,7S,8S)-5-(cyclopropylmethyl)-8-methoxy-4,7,10-trimethyl-11-oxo-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]-4-oxanecarboxamide
C27H41N3O5 (487.30460560000006)
N-[(4S,7S,8R)-5-(cyclopropylmethyl)-8-methoxy-4,7,10-trimethyl-11-oxo-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]-4-oxanecarboxamide
C27H41N3O5 (487.30460560000006)
N-[(4S,7R,8S)-5-(cyclopropylmethyl)-8-methoxy-4,7,10-trimethyl-11-oxo-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]oxane-4-carboxamide
C27H41N3O5 (487.30460560000006)
N-[(4S,7R,8R)-5-(cyclopropylmethyl)-8-methoxy-4,7,10-trimethyl-11-oxo-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]oxane-4-carboxamide
C27H41N3O5 (487.30460560000006)
N-[(4R,7S,8R)-5-(cyclopropylmethyl)-8-methoxy-4,7,10-trimethyl-11-oxo-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]-4-oxanecarboxamide
C27H41N3O5 (487.30460560000006)
N-[(4S,7S,8S)-5-(cyclopropylmethyl)-8-methoxy-4,7,10-trimethyl-11-oxo-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]-4-oxanecarboxamide
C27H41N3O5 (487.30460560000006)
N-[(4R,7R,8R)-5-[cyclopentyl(oxo)methyl]-8-methoxy-4,7,10-trimethyl-11-oxo-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]butanamide
C27H41N3O5 (487.30460560000006)
N-[(4S,7R,8R)-5-[cyclopentyl(oxo)methyl]-8-methoxy-4,7,10-trimethyl-11-oxo-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]butanamide
C27H41N3O5 (487.30460560000006)
N-[(5S,6S,9S)-5-methoxy-3,6,9-trimethyl-8-(4-oxanylmethyl)-2-oxo-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]cyclopropanecarboxamide
C27H41N3O5 (487.30460560000006)
N-[(5S,6S,9R)-5-methoxy-3,6,9-trimethyl-8-(4-oxanylmethyl)-2-oxo-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]cyclopropanecarboxamide
C27H41N3O5 (487.30460560000006)
N-[(5S,6S,9S)-5-methoxy-3,6,9-trimethyl-2-oxo-8-(1-oxopropyl)-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]cyclohexanecarboxamide
C27H41N3O5 (487.30460560000006)
N-[(5R,6S,9R)-5-methoxy-3,6,9-trimethyl-2-oxo-8-(1-oxopropyl)-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]cyclohexanecarboxamide
C27H41N3O5 (487.30460560000006)
N-[(4R,7R,8S)-5-(cyclopropylmethyl)-8-methoxy-4,7,10-trimethyl-11-oxo-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]-4-oxanecarboxamide
C27H41N3O5 (487.30460560000006)
N-[(4R,7R,8R)-5-(cyclopropylmethyl)-8-methoxy-4,7,10-trimethyl-11-oxo-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]-4-oxanecarboxamide
C27H41N3O5 (487.30460560000006)
N-[(4S,7R,8S)-5-[cyclopentyl(oxo)methyl]-8-methoxy-4,7,10-trimethyl-11-oxo-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]butanamide
C27H41N3O5 (487.30460560000006)
N-[(4R,7S,8R)-5-[cyclopentyl(oxo)methyl]-8-methoxy-4,7,10-trimethyl-11-oxo-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]butanamide
C27H41N3O5 (487.30460560000006)
N-[(4S,7S,8R)-5-[cyclopentyl(oxo)methyl]-8-methoxy-4,7,10-trimethyl-11-oxo-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]butanamide
C27H41N3O5 (487.30460560000006)
N-[(4R,7S,8S)-5-[cyclopentyl(oxo)methyl]-8-methoxy-4,7,10-trimethyl-11-oxo-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]butanamide
C27H41N3O5 (487.30460560000006)
N-[(4S,7S,8S)-5-[cyclopentyl(oxo)methyl]-8-methoxy-4,7,10-trimethyl-11-oxo-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]butanamide
C27H41N3O5 (487.30460560000006)
N-[(5S,6R,9R)-5-methoxy-3,6,9-trimethyl-8-(4-oxanylmethyl)-2-oxo-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]cyclopropanecarboxamide
C27H41N3O5 (487.30460560000006)
N-[(5R,6R,9R)-5-methoxy-3,6,9-trimethyl-8-(4-oxanylmethyl)-2-oxo-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]cyclopropanecarboxamide
C27H41N3O5 (487.30460560000006)
N-[(5R,6R,9S)-5-methoxy-3,6,9-trimethyl-8-(4-oxanylmethyl)-2-oxo-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]cyclopropanecarboxamide
C27H41N3O5 (487.30460560000006)
N-[(5R,6S,9R)-5-methoxy-3,6,9-trimethyl-8-(4-oxanylmethyl)-2-oxo-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]cyclopropanecarboxamide
C27H41N3O5 (487.30460560000006)
N-[(5S,6R,9S)-5-methoxy-3,6,9-trimethyl-8-(4-oxanylmethyl)-2-oxo-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]cyclopropanecarboxamide
C27H41N3O5 (487.30460560000006)
N-[(5R,6R,9R)-5-methoxy-3,6,9-trimethyl-2-oxo-8-(1-oxopropyl)-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]cyclohexanecarboxamide
C27H41N3O5 (487.30460560000006)
N-[(5R,6R,9S)-5-methoxy-3,6,9-trimethyl-2-oxo-8-(1-oxopropyl)-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]cyclohexanecarboxamide
C27H41N3O5 (487.30460560000006)
N-[(5S,6S,9R)-5-methoxy-3,6,9-trimethyl-2-oxo-8-(1-oxopropyl)-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]cyclohexanecarboxamide
C27H41N3O5 (487.30460560000006)
N-[(5S,6R,9R)-5-methoxy-3,6,9-trimethyl-2-oxo-8-(1-oxopropyl)-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]cyclohexanecarboxamide
C27H41N3O5 (487.30460560000006)
N-[(5S,6R,9S)-5-methoxy-3,6,9-trimethyl-2-oxo-8-(1-oxopropyl)-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]cyclohexanecarboxamide
C27H41N3O5 (487.30460560000006)
(3R,20R)-20-[(2R,3R,5R,6S)-3,5-dihydroxy-6-methyloxan-2-yl]oxy-3-hydroxyhenicosanoate
(3R)-21-[(2R,3R,5R,6S)-3,5-dihydroxy-6-methyloxan-2-yl]oxy-3-hydroxyhenicosanoate
2-aminoethyl [2-hydroxy-3-[(8Z,11Z,14Z,17Z)-icosa-8,11,14,17-tetraenoxy]propyl] hydrogen phosphate
C25H46NO6P (487.30625860000004)
(4E,8E)-3-hydroxy-2-(undecanoylamino)pentadeca-4,8-diene-1-sulfonic acid
C26H49NO5S (487.3331264000001)
(4E,8E)-3-hydroxy-2-(tridecanoylamino)trideca-4,8-diene-1-sulfonic acid
C26H49NO5S (487.3331264000001)
(4E,8E)-3-hydroxy-2-(tetradecanoylamino)dodeca-4,8-diene-1-sulfonic acid
C26H49NO5S (487.3331264000001)
(E)-3-hydroxy-2-[[(Z)-pentadec-9-enoyl]amino]undec-4-ene-1-sulfonic acid
C26H49NO5S (487.3331264000001)
(E)-2-[[(Z)-hexadec-9-enoyl]amino]-3-hydroxydec-4-ene-1-sulfonic acid
C26H49NO5S (487.3331264000001)
(4E,8E)-2-(decanoylamino)-3-hydroxyhexadeca-4,8-diene-1-sulfonic acid
C26H49NO5S (487.3331264000001)
(4E,8E)-2-(dodecanoylamino)-3-hydroxytetradeca-4,8-diene-1-sulfonic acid
C26H49NO5S (487.3331264000001)
(E)-3-hydroxy-2-[[(Z)-tetradec-9-enoyl]amino]dodec-4-ene-1-sulfonic acid
C26H49NO5S (487.3331264000001)
2-[[(9Z,12Z)-hexadeca-9,12-dienoyl]amino]-3-hydroxydecane-1-sulfonic acid
C26H49NO5S (487.3331264000001)
(E)-3-hydroxy-2-[[(Z)-tridec-9-enoyl]amino]tridec-4-ene-1-sulfonic acid
C26H49NO5S (487.3331264000001)
4-(3-Heptanoyloxy-2-nonanoyloxypropoxy)-2-(trimethylazaniumyl)butanoate
C26H49NO7 (487.35088440000004)
4-[2,3-Di(octanoyloxy)propoxy]-2-(trimethylazaniumyl)butanoate
C26H49NO7 (487.35088440000004)
4-(3-Propanoyloxy-2-tridecanoyloxypropoxy)-2-(trimethylazaniumyl)butanoate
C26H49NO7 (487.35088440000004)
4-(3-Butanoyloxy-2-dodecanoyloxypropoxy)-2-(trimethylazaniumyl)butanoate
C26H49NO7 (487.35088440000004)
4-(3-Pentanoyloxy-2-undecanoyloxypropoxy)-2-(trimethylazaniumyl)butanoate
C26H49NO7 (487.35088440000004)
4-(3-Acetyloxy-2-tetradecanoyloxypropoxy)-2-(trimethylazaniumyl)butanoate
C26H49NO7 (487.35088440000004)
4-(2-Decanoyloxy-3-hexanoyloxypropoxy)-2-(trimethylazaniumyl)butanoate
C26H49NO7 (487.35088440000004)
(1s,2r,5s,7r,8r,11s,14s)-1,2-dimethyl-18-(3-methylbut-2-en-1-yl)-7-(prop-1-en-2-yl)-6-oxa-23-azahexacyclo[12.10.0.0²,¹¹.0⁵,¹⁰.0¹⁶,²⁴.0¹⁷,²²]tetracosa-9,16(24),17,19,21-pentaene-8,11-diol
[6-(2-{2-[5-(6-ethyl-5-methyl-3,6-dihydro-2h-pyran-2-yl)-3-methylhexa-1,4-dien-1-yl]-3-methylcyclopropyl}ethenyl)-5-hydroxy-4-(methylamino)oxan-2-yl]acetic acid
C29H45NO5 (487.32975600000003)
(1s,4s,10s,12s)-12-{[(1s,4as,8as)-5,5,8a-trimethyl-2-methylidene-hexahydro-1h-naphthalen-1-yl]methyl}-2,8,19-triazapentacyclo[10.7.0.0²,¹⁰.0⁴,⁸.0¹³,¹⁸]nonadeca-13,15,17-triene-3,9-dione
23-o-acetyl-12β-hydroxysolasodine
C29H45NO5 (487.32975600000003)
{"Ingredient_id": "HBIN004134","Ingredient_name": "23-o-acetyl-12\u03b2-hydroxysolasodine","Alias": "23-O-acetyl-12\u03b2-hydroxysolasodine","Ingredient_formula": "C29H45NO5","Ingredient_Smile": "C29H45NO5","Ingredient_weight": "487.67","OB_score": "12.16578116","CAS_id": "117803-97-1","SymMap_id": "SMIT08805","TCMID_id": "37260","TCMSP_id": "MOL007352","TCM_ID_id": "NA","PubChem_id": "NA","DrugBank_id": "NA"}
(3r,6s,9s,13s)-9-benzyl-3-[(2s)-butan-2-yl]-13-[(2s)-hexan-2-yl]-5,8,11-trihydroxy-6-methyl-1-oxa-4,7,10-triazacyclotrideca-4,7,10-trien-2-one
C27H41N3O5 (487.30460560000006)
(3r,6s,9s,13s)-9-benzyl-3-[(2r)-butan-2-yl]-13-[(2s)-hexan-2-yl]-5,8,11-trihydroxy-6-methyl-1-oxa-4,7,10-triazacyclotrideca-4,7,10-trien-2-one
C27H41N3O5 (487.30460560000006)
(5z)-3-[(1r,2s,4as,6s,8ar)-3,4a,6-trimethyl-2-[(2e,4r)-4-methylhex-2-en-2-yl]-2,5,6,7,8,8a-hexahydro-1h-naphthalene-1-carbonyl]-5-[(4-hydroxyphenyl)methylidene]pyrrol-2-ol
(5z)-3-[(1s,2s,4ar,6s,8ar)-3,4a,6-trimethyl-2-[(2e,4s)-4-methylhex-2-en-2-yl]-2,5,6,7,8,8a-hexahydro-1h-naphthalene-1-carbonyl]-5-[(4-hydroxyphenyl)methylidene]pyrrol-2-ol
3-[3,4a,6-trimethyl-2-(4-methylhex-2-en-2-yl)-2,5,6,7,8,8a-hexahydro-1h-naphthalene-1-carbonyl]-5-[(4-hydroxyphenyl)methylidene]pyrrol-2-ol
n-{3-[(5z,8z,11z)-n-(5-carbamimidamidopentyl)tetradeca-5,8,11-trienamido]propyl}-3-methylbut-2-enimidic acid
3-(acetyloxy)-4-(dodecanoyloxy)-n-(2-hydroxy-4-methoxy-4-oxobutyl)-2-methylpentanimidic acid
(1s,2r,3s,7r,11s,13s,14r)-2-[(3s)-3-[(1r,4s,5s)-1,4-dimethyl-2,8-dioxabicyclo[3.2.1]octan-4-yl]-3-hydroxypropyl]-14-isopropyl-1-methyl-12-azapentacyclo[8.6.0.0²,¹³.0³,⁷.0⁷,¹²]hexadecan-11-ol
C30H49NO4 (487.36613940000007)
(1s,2r,3s,7r,10s,11s,13s,14r)-2-[(3s)-3-[(1r,4s,5s)-1,4-dimethyl-2,8-dioxabicyclo[3.2.1]octan-4-yl]-3-hydroxypropyl]-14-isopropyl-1-methyl-12-azapentacyclo[8.6.0.0²,¹³.0³,⁷.0⁷,¹²]hexadecan-11-ol
C30H49NO4 (487.36613940000007)
[(2s,4s,5r,6s)-6-[(1e)-2-[(1s,2s,3r)-2-[(1e,3r,4e)-5-[(2r,6r)-6-ethyl-5-methyl-3,6-dihydro-2h-pyran-2-yl]-3-methylhexa-1,4-dien-1-yl]-3-methylcyclopropyl]ethenyl]-5-hydroxy-4-(methylamino)oxan-2-yl]acetic acid
C29H45NO5 (487.32975600000003)
(1s,2r,5s,7r,8r,11s,14s)-1,2-dimethyl-20-(2-methylbut-3-en-2-yl)-7-(prop-1-en-2-yl)-6-oxa-23-azahexacyclo[12.10.0.0²,¹¹.0⁵,¹⁰.0¹⁶,²⁴.0¹⁷,²²]tetracosa-9,16(24),17,19,21-pentaene-8,11-diol
1,2-dimethyl-18-(3-methylbut-2-en-1-yl)-7-(prop-1-en-2-yl)-6-oxa-23-azahexacyclo[12.10.0.0²,¹¹.0⁵,¹⁰.0¹⁶,²⁴.0¹⁷,²²]tetracosa-9,16(24),17,19,21-pentaene-8,11-diol
1,2-dimethyl-20-(2-methylbut-3-en-2-yl)-7-(prop-1-en-2-yl)-6-oxa-23-azahexacyclo[12.10.0.0²,¹¹.0⁵,¹⁰.0¹⁶,²⁴.0¹⁷,²²]tetracosa-9,16(24),17,19,21-pentaene-8,11-diol
2-(3-{1,4-dimethyl-2,8-dioxabicyclo[3.2.1]octan-4-yl}-3-hydroxypropyl)-14-isopropyl-1-methyl-12-azapentacyclo[8.6.0.0²,¹³.0³,⁷.0⁷,¹²]hexadecan-11-ol
C30H49NO4 (487.36613940000007)
(3r,6s,9s,13s)-9-benzyl-13-[(2s)-hexan-2-yl]-5,8,11-trihydroxy-6-methyl-3-(2-methylpropyl)-1-oxa-4,7,10-triazacyclotrideca-4,7,10-trien-2-one
C27H41N3O5 (487.30460560000006)
9-benzyl-13-(hexan-2-yl)-5,8,11-trihydroxy-6-methyl-3-(2-methylpropyl)-1-oxa-4,7,10-triazacyclotrideca-4,7,10-trien-2-one
C27H41N3O5 (487.30460560000006)
(5z)-3-[(1r,2s,4as,6s,8ar)-3,4a,6-trimethyl-2-[(2e)-4-methylhex-2-en-2-yl]-2,5,6,7,8,8a-hexahydro-1h-naphthalene-1-carbonyl]-5-[(4-hydroxyphenyl)methylidene]pyrrol-2-ol
9-benzyl-13-hexyl-5,8,11-trihydroxy-6-methyl-3-(2-methylpropyl)-1-oxa-4,7,10-triazacyclotrideca-4,7,10-trien-2-one
C27H41N3O5 (487.30460560000006)
n-{3-[n-(5-carbamimidamidopentyl)tetradeca-5,8,11-trienamido]propyl}-3-methylbut-2-enimidic acid
(3r,6s,9s,13r)-9-benzyl-13-hexyl-5,8,11-trihydroxy-6-methyl-3-(2-methylpropyl)-1-oxa-4,7,10-triazacyclotrideca-4,7,10-trien-2-one
C27H41N3O5 (487.30460560000006)
3-(acetyloxy)-4-(dodecanoyloxy)-n-[(2r)-2-hydroxy-4-methoxy-4-oxobutyl]-2-methylpentanimidic acid
9-benzyl-13-(hexan-2-yl)-5,8,11-trihydroxy-6-methyl-3-(sec-butyl)-1-oxa-4,7,10-triazacyclotrideca-4,7,10-trien-2-one
C27H41N3O5 (487.30460560000006)